Last reviewed · How we verify

NCT05852288

Role of Inflammation in Carpal Tunnel Syndrome

Status unknown Last updated 10 May 2023
What this trial tests

trial testing Inflammatory markers in Carpal Tunnel Syndrome in 50 participants. Status unknown.

Timeline
15 May 2023
Primary endpoint
1 September 2023
15 September 2023

Quick facts

Lead sponsorAhram Canadian University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment50
Start date15 May 2023
Primary completion1 September 2023
Estimated completion15 September 2023
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ahram Canadian University

Who can join

Adults 18 to 60, any sex, with Carpal Tunnel Syndrome or Median Neuropathy, Carpal Tunnel. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the role of inflammation in carpal tunnel syndrome (CTS) using a prospective cohort study design. The study will involve a sample of at least 50 individuals with CTS who will undergo a comprehensive clinical and biochemical evaluation to assess the role of inflammation in CTS. The primary outcome measures include inflammatory markers, such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), as well as clinical measures of CTS severity. Data will be analyzed using regression analysis to determine the relationship between inflammation and CTS. The study is expected to provide information on the role of inflammation in CTS and inform the choice of drug and concentration for transdermal drug administration.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Inflammatory markers

Trials testing the same drug.

Other recruiting trials for Carpal Tunnel Syndrome

Currently open trials in the same condition.

Other Ahram Canadian University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05852288.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing